Recombinant nucleic acid of seneca virus, recombinant vaccine strain as well as preparation method and application thereof
A recombinant nucleic acid, recombinant vaccine technology, applied in the field of genetic engineering, can solve problems such as indistinguishability, achieve high titer, achieve innovation, and achieve the effect of great application value
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0081] The present invention also provides a preparation method of the Seneca recombinant vaccine, comprising the following steps:
[0082] 1) Inoculating the Seneca recombinant virus into susceptible cells for proliferation and culture to obtain the Seneca recombinant virus liquid;
[0083] 2) Inactivating and emulsifying the Seneca recombinant virus in the Seneca recombinant virus liquid to obtain the Seneca recombinant vaccine.
[0084] The susceptible cells described in step 1) of the present invention preferably include BHK-21 cells, PK-15 cells, ST cells, SK-RST cells, IBRS-2 cells, H1299 cells or 293T cells, more preferably BHK-21 suspension cells or ST suspension cells.
[0085] In the present invention, when carrying out the proliferation culture described in step 1), the virus titer of the Seneca recombinant virus is preferably not less than 10 6.5 TCID 50 / mL, more preferably 10 6.5 TCID 50 / mL~10 10.0 TCID 50 / mL. The Seneca recombinant virus strain of the ...
Embodiment 1
[0095] Construction of infectious clones of Seneca recombinant virus:
[0096] The SVV / FJ / 001 strain is preserved in the China Center for Type Culture Collection (microorganism collection number: CCTCCNO.V201802), (disclosed in the authorized patent "Seneca Valley virus vaccine and its preparation method and application" ZL201810003888.2, which The full text is incorporated in this application by reference), according to the SVA genome sequence (Genebank: KY747510), design synthetic amplification primers:
[0097] SVA-1F0: 5'-gtgaggacgaaactataggaaaggaattcctatagtcttgaaagggggggctgggcc-3' (SEQ ID NO. 2);
[0098] SVA-1F: 5'-ataggt ttaattaa tgttaagcgtctgatgagtccgtgaggacgaaactatagga-3' (SEQ ID NO. 3);
[0099] SVA-1R: 5'-gggaa gcatgc tggggcaccaggcac-3' (SEQ ID NO. 4);
[0100] SVA-2F: 5'-cccca gcatgc ttccctttcgcagc-3' (SEQ ID NO. 5);
[0101] SVA-2R: 5'-ttttctaga gcggccgc t 38 -3' (SEQ ID NO. 6);
[0102] SVA-m5UTRF: 5'-gttctagcctactcgttttttcccctactcactcattcgtgttgtaact...
Embodiment 2
[0109] Rescue of Seneca Recombinant Virus and Culture Properties of Different Cells
[0110] 2.1 Rescue of Seneca recombinant virus
[0111] use Plasmid Plus Maxi Kit (QIAGEN company) prepares the recombinant plasmid prSVV / FJ-M that obtains by embodiment 1, is used for transfection when BHK-21 cell grows to 80%, under the mediation of liposome LipofectamineTM2000 (Invitrogen) Transfect 4 μg of the recombinant plasmid into BHK-21 cells, and set up liposome control and normal cell control at the same time, and place them in a place containing 5% CO 2 In a 37°C incubator, discard the supernatant after 6 hours of transfection, add MEM medium, continue to culture, observe the cell state and cell pathological changes, harvest the virus when about 90% of the cells are pathological, and freeze and thaw three times. BHK-21 cells were inoculated again until the virus could stably produce cytopathic changes, and the cells became round and shed, gradually forming plaques and disintegra...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com